(7) To prevent the grant of patents for the medicinal use of plants which have long been in use in ISM.

(8) To encourage medical-tourism and promote ISM in foreign countries.

Nucleus Cochlear Implant Facility for impaired persons

1397. SHRI YADLAPATIVENKAT RAO: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether a new advanced medical device called "Nucleus Cochlear Implant Facility" can help severely impaired persons to hear speech and sounds has been developed;

(b) whether it has been acquired by All India Institute of Medical Sciences for offering this facility to needy persons;

(c) whether this facility will be acquired on a large scale and made available to all major hospitals; and

(d) the other details in this regard?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. C.P. THAKUR): (a) to (d) Nucleus Cochlear Implant Facility, an electronic device which is surgically implanted in a hearing-impaired individual's ear, has been developed by Cochlear Corporation (Australia). Research has indicated that patients are able to perceive speech better through the multichannel cochlear implants than through single cochlear implants. In All India Institute of Medical Sciences, this facility is offered to suitable persons after proper evaluation for such an implant surgery. The cost of the multichannel cochlear implant is approximately Rs. 7.5 lakhs, for the implant and surgery. At present, there is no proposal to provide this facility on a large scale in major hospitals due to the cost factor and other operational difficulties.

Doctors gone to foreign countries for higher studies

1398. SHRIMATI SAROJ DUBEY: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that a large number of doctors with post graduate degrees in various subjects had gone to United States and other foreign countries to acquire higher degrees in heir respective fields and did not return to the country after completing their studies for want of proper opportunities in the
country;

(b) whether Government have assessed this situation; and

(c) if so, the measures Government propose to take to attract them in the country by providing proper job opportunities within India?

THE MINISTER OF HEALTH AND FAMILY WELFARE(DR. C.P. THAKUR): (a) to (c) The information is being collected and will be laid on the table of House.

Variants of Dispirin

1399. SHRI P. PRABHAKAR REDDY: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Dispirin, the popular analgesic pharmaceutical medicine has undergone a major restructuring;

(b) if so, the details thereof and the reasons therefor;

(c) the different variants of this medicine to be manufactured and the different diseases, each of the variants is expected to take care of; and

(d) by when these variants are likely to reach the market?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. C.P. THAKUR): (a) and (b) M/s Reckitt Benekiser (I) Ltd., Mysore who were marketing soluble Aspirin 3.25 mg. Tablet under the brand name "DISPRJN" were permitted by Drugs Controller, Karnataka to change to "DISPRIN PLUS" with the composition Paracetamol I.P. 500 mg. per tablet. The firm was however, directed that the label of Dispirin Plus shall bear the words. "New Formula" for two years.

Since the new brand /.e.'Disprin Plus' was considered misleading as there was no addition of any therapeutic ingredients to the earlier formulations of Disprin containing Aspirin, the matter was taken up with the Drugs Controller, Karnataka to review the permission granted by them.

Drugs Controller, Karnataka has informed that an order was passed on 8.11.2001 to stop the production and distribution of'Disprin Plus[1] tablets. Fresh permission to change the name of the product from Disprin Plus to 'Disprin Paracetamol has been granted to the firm as this product contains Paracetamol and not Aspirin.

(c) and (d) Aspirin in lower dose is indicated in case of increased risk of blood clotting, myocardial ir.faraction *etc.* M/s Reckitt Benekiser is marketing Aspirin